1. Articles from news.prnewswire.com

  2. 1-19 of 19
    1. Volcano Corporation Praises FAME Study Results

      FAME two-year results show FFR-Guided PCI reduces death and heart attacks by 34% and may reduce heart procedure costs by billions. SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that the two-year results of the Fractional Flow Reserve (FFR) vs. Angiography for Multivessel Evaluation (FAME) study confirm the importance of FFR in improving patient outcomes and reducing hospital costs. The findings were released today during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco. The ...
      Read Full Article
    2. Pre-clinical Data Show OrbusNeich's Combo Bio-engineered Sirolimus Eluting Stent May Offer Advantages to Current Drug Eluting Stent Technologies

      SAN FRANCISCO, Sept. 23 /PRNewswire/ -- OrbusNeich announced today that pre-clinical data involving porcine coronary models demonstrate that the company's Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) may offer advantages to the Cypher(R) sirolimus eluting stent and the XIENCE(TM) V everolimus eluting stent. Specifically, histological and optical coherence tomography (OCT) data out to 28 days show that the Combo Stent had lower neointimal hyperplasia and stenosis, as well as lower inflammation and fewer giant cells on the stent struts. The data were presented by Juan F. Granada, M.D., medical director of the Skirball Center for Cardiovascular Research ...
      Read Full Article
    3. LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009

      LightLab to Host Symposium at TCT Featuring World's Highest Resolution OCT System for Intracoronary Imaging WESTFORD, Mass., Sept. 18 /PRNewswire/ -- LightLab Imaging Inc., the pioneer and leader in the development of Optical Coherence Tomography (OCT) for intravascular and other applications, announced today that it will showcase its advanced FD-OCT(TM) technology, the C7-XR(TM) imaging system, at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, CA starting Monday, September 21 through Friday, September 25, 2009. During TCT, LightLab will host a breakfast symposium at which leading interventional cardiologists will present the emerging "gold standard" for Frequency Domain OCT ...
      Read Full Article
    4. Volcano Corporation Presentation at Weisel Conference to be Webcast

      SAN DIEGO, Sept. 1 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Thomas Weisel Partners Healthcare Conference 2009 on Wednesday, September 9. The presentation by John Dahldorf, chief financial officer, will begin at 8 a.m., East
      Read Full Article
    5. Volcano Corporation and Siemens Healthcare Announce Global Resale Agreement for Volcano IVUS/FFR Systems

      SAN DIEGO and ERLANGEN, GERMANY, Aug. 25 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, announced today that it has entered into a non-exclusive, global resale agreement with Siemens Healthcare, a sector of Siemens AG (NYSE: SI). Under this agreement, Siemens will resell Volcano-branded s5i IVUS/FFR systems and accessories alongside Siemens' Artis family of X-ray systems. The Volcano s5i intravascular ultrasound (IVUS) and fractional flow reserve (FFR) system is compatible with Artis X-ray offerings. Volcano's s5i is a component-based system that is ...
      Read Full Article
    6. Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast

      SAN DIEGO, Aug. 7 /PRNewswire-FirstCall/ -- Volcano Corporation (Nadsaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it will be participating in the Canaccord Adams 29th Annual Global Growth Conference on Thursday, August 13. The presentation by Scott Huennekens, president and chief executive officer, will begin at 11:30 a.m., Eastern Daylight Time (8:30 a.m., Pacific Daylight Time).
      Read Full Article
    7. Volcano Reports 30 Percent Increase in Second Quarter Revenues

      CORE IVUS AND FM BUSINESSES GROW 21 PERCENT, DRIVEN BY DISPOSABLE SALES AND CONSOLE PLACEMENTS SAN DIEGO, Aug. 4 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported revenues of $54.0 million for the second quarter of fiscal 2009. The results for the quarter ended June 30,
      Read Full Article
    8. Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman

      Volcano Achieves Major Milestone in Japan Direct Sales Initiative With Signing of Termination Agreement With Goodman
      SAN DIEGO, July 8 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, said today it has signed a termination agreement with its largest distributor in Japan, Goodman Company, Ltd. This agreement, which took effect today, will enable Volcano to accelerate its transition to a direct sales force in the market to support its intravascular ultrasound (IVUS) and Functional Measurement (FM) consoles and disposables, as well as products currently in development.
      Read Full Article
    9. vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

      Six-Month Follow-Up Shows Reduced Stenosis, Healthy Endothelial Regrowth in Vessel Treated Proactively for Vulnerable Plaque DOYLESTOWN, Pa., June 1 /PRNewswire/ -- Six months after placement of a vProtect(TM) Luminal Shield to treat a "vulnerable" plaque, a follow-up exam revealed reduced plaque burden and reduced stenosis in the target vessel. The exam was part of the SECRITT I trial, a randomized study designed to evaluate the vProtect(
      Read Full Article
    10. Volcano Announces OCT Activities at EuroPCR 2009

      Volcano's Axsun Laser - At the Heart of OCT SAN DIEGO and BARCELONA, Spain, May 19 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis of coronary and peripheral artery disease, today highlights its technology leadership position in the emerging field of Optical Coherence Tomography (OCT) at the EuroPCR conference in Barcelona, Spain. Volcano's wholly owne
      Read Full Article
    11. Volcano Announces Worldwide Exclusive Distribution Agreement With Lumen Biomedical for Xtract(TM) Thrombus Aspiration Catheter

      SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced an exclusive worldwide distribution agreement to initiate the formal launch of the Xtract(TM) thrombus aspiration catheter, manufactured by Lumen Biomedical. The Xtract(TM) thrombus aspiration catheter is available for immediate sale in the U.S. and Europe. This marks Volcano's entry into what we believe is a $70+ million aspiration market.
      Read Full Article
    12. Volcano Reports First Quarter Revenues of $49.0 Million; IVUS and FM Businesses Grew 24 Percent

      The revenues for the first quarter of 2009 include $3.7 million from Axsun Technologies, Inc., which Volcano acquired at the end of 2008 and for which the company recorded no revenues in the first quarter a year ago. The company said revenue growth was ...
      Read Full Article
    13. Volcano Corporation Schedules First Quarter Conference Call, Webcast

      SAN DIEGO, April 27 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report its operating results for the first quarter of fiscal 2009 on Tuesday, May 5. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Daylight Time (5 p.m., Eastern Daylight Time), Tuesday, May 5, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial ...
      Read Full Article
    14. Volcano Reports Full Year Revenues Increase 31 Percent

      FOURTH QUARTER REVENUES INCREASE 23 PERCENT SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today reported that revenues for the full year 2008 increased 31 percent over full year 2007 and that revenues for the fourth quarter of 2008 increased 23 percent over revenues in the fourth quarter of 2007. For the year ended December
      Read Full Article
    15. Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast

      SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced that it will report is operating results for the fourth quarter and all of fiscal 2008 on Tuesday, February 17. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Stan
      Read Full Article
    16. Volcano Announces Closing of Axsun Technologies Acquisition

      SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it has closed its previously announced acquisition of Axsun Technologies, Inc. Axsun is a leading developer and manufacturer of lasers and optical engines used in medical Optical Coherence Tomography (OCT) imaging systems and advanced photonic components and subsy
      Read Full Article
    17. Volcano Corporation Schedules Conference Call, Webcast to Discuss Axsun Transaction

      SAN DIEGO, Jan. 5 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, will conduct a conference call and webcast Tuesday, January 6, to discuss its acquisition of Axsun Technologies, Inc., that was announced on December 23, 2008. The teleconference call and webcast will begin at 1 p.m., Eastern Standard Time (10 a.m., Pacific Standard Time), and ca
      Read Full Article
    18. Volcano Announces Acquisition of Axsun Technologies, Inc. for $21.5M

      Volcano Announces Acquisition of Axsun Technologies, Inc.  for $21.5M
      Volcano Corporation, a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, said today that it has entered into a definitive agreement to acquire Axsun Technologies, Inc., a privately-held company that is a leading developer and manufacturer of lasers and optical engines used in medical Optical Coherence Tomography (OCT) imaging systems and advanced photonic components and subsystems used in other industrial applications.
      Read Full Article
    19. Nikon Instruments and Thorlabs Together Bring OCT Imaging to the FN1 'Physiostation' Microscope

      Pairing Allows Deep Imaging for Live Cell and Live Animal Researchers MELVILLE, N.Y., Nov. 17/PRNewswire/ --Nikon Instruments, Inc. (www.nikoninstruments.com) and Thorlabs, Inc. (www.thorlabs.com) have collaborated to bring Optical Coherence Tomography (OCT) to Nikon's FN1 "PhysioStation" upright focusing nosepiece microscope system for Neurophysiology and in vivo, small-animal studies. Ideal for neuroscience and electrophysiology applications, the new OCT system enables an imaging depth of 2-3
      Read Full Article
    1-19 of 19
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks